Cell-free plasma next-generation sequencing assists in the evaluation of secondary pneumonia in patients with COVID-19: a case series.

Joshua A David, Bharadhwaj Kolipakkam, Megan K Morales, Nicole C Vissichelli

Abstract read

In one paragraph

Article in Epidemiology and infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Refining the Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in High-Risk Population of Infection: A Narrative Review.Infection and drug resistance · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Joshua A DavidVirginia Commonwealth University School of Medicine, Richmond, VA, USA.

Bharadhwaj KolipakkamDivision of Hematology, Oncology and Palliative Care, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.

Megan K MoralesDivision of Infectious Diseases, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.

Nicole C VissichelliDivision of Infectious Diseases, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.ORCID 0000-0002-7748-1215

Funding

SURFACE GLYCOPROTEINS IN T BRUCEIS14RR002649 · NCRR · SHAW UNIVERSITY · PI BASKERVILLE, EUGENE N · 1985 to 1987

–

6 · The paper itself

Abstract

Secondary pneumonia occurs in 8-24% of patients with Coronavirus 2019 (COVID-19) infection and is associated with increased morbidity and mortality. Diagnosis of secondary pneumonia can be challenging. The purpose of this study was to evaluate the use of plasma microbial cell free DNA sequencing (mcfNGS) in the evaluation of secondary pneumonia after COVID-19. We performed a single-center case series of patients with COVID-19 who underwent mcfNGS to evaluate secondary pneumonia and reported the organisms identified, concordance with available tests, clinical utility, and outcomes. In 8/13 (61%) cases, mcfNGS detected 1-6 organisms, with clinically significant organisms identified in 4 cases, including

Indexed as

Anti-Infective AgentsCOVID-19Pneumocystis cariniiPneumonia, PneumocystisHigh-Throughput Nucleotide SequencingHumansAnti-Infective Agentscell-free microbial DNACOVID-19immunocompromised hostKariuspneumonia

Identifiers

PMID37886888

DOI10.1017/S0950268823001711

PMCPMC10644058

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.